¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody forming cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
¿µ¹® stem cell ÇÑ±Û Áٱ⼼Æ÷, °£¼¼Æ÷
¼³¸í   
  Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼­ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐÈ­¸¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇϴ ¼¼Æ÷·Î¼­ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ Àִ ¼¼Æ÷·Î¼­ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼­ ºÐÈ­µÇ¾î ¹ß»ýÇÑ´Ù.
¿µ¹® renal cell carcinoma ÇÑ±Û ÄáÆÏ¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ ¾Ï. ÁַΠ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀΠ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸À̴ ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈ­Çпä¹ýÀ̸砾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ Àִ °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù.
¿µ¹® squamous cell carcinoma ÇÑ±Û ÆíÆò¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼­, ÆíÆò¼¼Æ÷°¡ Àִ ¾î¶² °÷¿¡¼­µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼­ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀڱþϠµîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. Æ¯È÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢È­Áõ¿¡¼­ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Æ¯¼ºÀ¸·Î¼­ °¢ÁúÀ» »ý¼ºÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antimitochondrial antibody
    Ç×¹ÌÅäÄܵ帮¾ÆÇ×ü, Ç׻縳üÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
  • anti-Ro antibody
    Ç×RoÇ×ü
  • anti-Sm antibody
    Ç×SmÇ×ü
  • antisperm antibody
    Ç×Á¤ÀÚÇ×ü
  • atypical antibody
    ºñÁ¤ÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
  • autoreactive antibody
    ÀÚ°¡¹ÝÀÀÇ×ü
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã½ºÇ×ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • hair cell
    Åм¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Kupffer's cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • packed red blood cell
    ³óÃàÀûÇ÷±¸
  • parietal cell
    º®¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • atypical antibody
    ÀÌÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
  • autoreactive antibody
    ÀÚ°¡¹ÝÀÀÇ×ü
  • bivalent antibody
    À̰¡Ç×ü
  • blocking antibody
    Â÷´ÜÇ×ü
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • chimeric antibody
    Ű¸Þ¶óÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Lewis antibody
    ·çÀ̽ºÇ×ü
  • Lutheran antibody
    ·çÅ×¶õÇ×ü
  • M2 antibody
    M2 Çü Ç×ü
  • P antibody
    P Ç×ü
  • Scl-70 antibody
    Scl-70 Ç×ü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • albumin agglutinating antibody
    ¾ËºÎ¹ÎÀÀÁýÇ×ü(¡­ëêó¢ù÷ô÷).
  • anti-La antibody
    Ç×LaÇ×ü
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • bronchiolar cell clara cell
    ¼¼±â°üÁö¼¼Æ÷
  • cell to cell cooperation
    ¼¼Æ÷°£ÇùÁ¶ÀÛ¿ë(á¬øàÊàúððàíÂéÄ).
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • clear cell basal cell carcinoma
    Åõ¸í¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • clear cell epinephrine cell
    ¹àÀº¼¼Æ÷ ¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • dark cell norepinephrine cell
    ¾îµÎ¿î¼¼Æ÷ ³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • interstitial cell dark cell
    »çÀÌÁú¼¼Æ÷
  • interstitial cell leydigs cell
    »çÀÌÁú¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • neurolemmal cell [schwanns cell]
    ½Å°æÁý¼¼Æ÷
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Follicular cell
    ³­Æ÷¼¼Æ÷
    [¿¾ ¿ë¾î] ³­Æ÷¼¼Æ÷
  • Endothelial cell
    ³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ³»ÇǼ¼Æ÷
  • Ependymal cell
    ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] »óÀǼ¼Æ÷
  • Secretory cell of lacrimal gland
    ´«¹°¼¼Æ÷
    [¿¾ ¿ë¾î] ´©¼±¼¼Æ÷
  • Delta cell
    µ¨Å¸¼¼Æ÷
    [¿¾ ¿ë¾î] µ¨Å¸¼¼Æ÷
  • Fat-storing cell
    µ¿±¼ÁÖÀ§Áö¹æ¼¼Æ÷
    [¿¾ ¿ë¾î] µ¿¾çÇ÷°üÁÖÀ§Áö¹æ¼¼Æ÷
  • Bipolar cell
    µÎ±Ø¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ç±Ø¼¼Æ÷
  • Spherical cell
    µÕ±Ù¼¼Æ÷
    [¿¾ ¿ë¾î] ±¸Çü¼¼Æ÷
  • Glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
    [¿¾ ¿ë¾î] ¸»Ãʱ³¼¼Æ÷
  • Choroid ependymal cell
    ¸Æ¶ô³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¸Æ¶ô»óÀǼ¼Æ÷
  • Dust cell
    ¸ÕÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ÕÁö¼¼Æ÷
  • Amacrine cell
    ¹«Ãà»è¼¼Æ÷
    [¿¾ ¿ë¾î] ¹«Ãà»è¼¼Æ÷
  • Polyhedral cell
    ¹µ¸éü¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù°¢Çü¼¼Æ÷
  • Polyhedral cell
    ¹µ¸éü¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù¸éü¼¼Æ÷
  • Multilocular fat cell
    ¹µÄ­Áö¹æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù¹æ¼ºÁö¹æ¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • coprecipitating antibody
    °øÄ§Àü(ÍìöØîþ) Ç×ü(ù÷ô÷)
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀ Ç×ü(Îßó©Úãëëù÷ô÷)
  • cytophilic antibody
    ¼¼Æ÷ģȭÇ×ü(á¬øàöÑûúù÷ô÷)
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼º Ç×ü(á¬øàÔ¸àõù÷ô÷)
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼º Ç×ü(á¬øàöÑûúàõù÷ô÷)
  • direct fluorescent antibody technique
    Á÷Á¢ Çü±¤ Ç×ü¼ú(òÁïÈû«ÎÃù÷ô÷âú)
  • ferritin-labeled antibody
    Æä¸®Æ¾Ç¥Áö(øöò½) Ç×ü(ù÷ô÷)
  • fluorescent antibody
    Çü±¤ Ç×ü(û«ÎÃù÷ô÷)
  • fluorescent antibody technique
    Çü±¤ Ç×ü¼ú(û«ÎÃù÷ô÷âú)
  • fraction-antibody binding
    ºÎºÐÇ×ü °áÇÕ(Ý»ÝÂù÷ô÷Ì¿ùê)
  • hemolytic antibody
    ¿ëÇ÷ Ç×ü(éÁúìù÷ô÷)
  • heterocytotropic antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü(ì¶ðúöÑûúàõù÷ô÷)
  • heterophile antibody
    ÀÌÈ£¼º Ç×ü(ì¶û¿àõù÷ô÷)
  • heterospecific antibody
    ÀÌÁ¾Æ¯ÀÌ Ç×ü(ì¶ðú÷åì¶ù÷ô÷)
  • homocytotropic antibody
    µ¿Á¾¼¼Æ÷ģȭ¼º Ç×ü(ÔÒðúá¬øàöÑûúàõù÷ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • islet cell adenoma
    Ãéµµ¼¼Æ÷¼±Á¾
  • islet cell carcinoma
    µµ¼¼Æ÷¾ÏÁ¾
  • Langerhans' cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langhans' glant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • large cell
    ´ë¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ¾ç¼¼Æ÷, ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ±¸¾ç¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    À¯µ¹ºÀ¼Ò
  • mastoid cell
    À¯(¾ç)µ¹(±â)ºÀ¼Ò
  • nerve cell
    ½Å°æ¼¼Æ÷
  • neuroepithelial cell
    ½Å°æ»óÇǼ¼Æ÷
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷, ½Å°æ±³¼¼Æ÷
  • olfactory cell
    Èİ¢(»óÇÇ)¼¼Æ÷, Èİ¢¼¼Æ÷
  • packed cell
    ÃæÀü¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
SCA self-care agency; severe congenital anomaly; sickle-cell anemia; single-camera autostereoscopic [ima...
PCA para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant...
AF abnormal frequency; acid-fast; adult female; afebrile; aflatoxin; albumin-free; albumose-free; aldeh...
CFA colonization factor antigen; colony-forming assay; complement-fixing antibody; complete Freund's adj...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
APC antibody producing cell
ADCC antibody-dependent cell mediated cytotoxic
PFU Plaque Forming Unit
AFC Ab forming cells
ARFC Autologous rosette-forming cells
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
  • circulating antibasement membrane antibody
    ¼øÈ¯ Ç×±âÀú¸· Ç×ü
  • cold reacting antibody
    ÇÑ·© Ç×ü
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
  • cytotoxic antibody
    ¼¼Æ÷ µ¶ Ç×ü, ¼¼Æ÷ µ¶¼º Ç×ü
  • deficient antibody syndrome
    Ç×ü °áÇÌ ÁõÈıº
  • donath-landsteiner antibody
    donath-landsteiner Ç×ü
  • double layer fluorescent antibody technique
    ÀÌÃþ Çü±¤ Ç×ü¹ý
  • enhancing antibody
    Áõ°­ Ç×ü
    µ¿Á¾ ÀÌ½Ä °ÅÀý ¹ÝÀÀÀÇ effector T ¼¼Æ÷ÀÇ ÀÛ¿ëÀ» ¹æÇØÇϰí ÀÌ½ÄÆíÀÇ »ýÂø ¿¬ÀåÀ» °¡Á®¿À´Â Ç×ü. ÁÖ·Î IgG classÀÇ ÀÌ½Ä Ç׿ø ƯÀÌ Ç×ü¸¦ ¸»ÇÑ´Ù.
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • enzyme labeled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • enzyme-labelled antibody
    È¿¼Ò Ç¥Áö Ç×ü
  • fluorescein-labelled antibody
    Çü±¤ Ç¥Áö Ç×ü
  • fluorescent antibody stain
    Çü±¤ Ç×ü ¿°»ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
antibody combining site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antibody deficiency disease <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody deficiency syndrome <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms.
See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency.
Synonym: antibody deficiency disease.
(05 Mar 2000)
antibody-dependent enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors.
(12 Dec 1998)
Antibody Directed Enzyme Prodrug Therapy <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately.
The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects.
Acronym: ADEPT
(14 Nov 1997)
antibody diversity The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • guard cell
    °øº¯¼¼Æ÷
  • hair cell
    À¯¸ð ¼¼Æ÷(ƯÈ÷ ÄÚ¸£Æ¼ ±â°ü µî¿¡ Àִ û°¢ ¼¼Æ÷)
  • hot cell
    ¹æ»ç¼º ¹°Áú 󸮿ë Â÷Æó½Ç
  • interstitial cell stimulating hormone
    °£¼¼Æ÷ ÀÚ±Ø È£¸£¸ó(ICSH)
  • memory cell
    (ÄÄÇ»ÅÍ)±â¾ï¼ÒÀÚ
  • mercuer cell
    ¼öÀº ÀüÁö
  • micelle,-cell
    ±³Áú ÀÔÀÚ;¹Ì¼¿
  • microbial cell
    ¹Ì»ý¹°ÀÇ ±Õü
  • narrow bed(cell)
    NARROW HOUSE
  • nerve cell
    ½Å°æ¼¼Æ÷
  • padded cell
    (´ÙÄ¡Áö ¾Ê°Ô º®¿¡ ÆÐµå¸¦ ´í)Á¤½Å º´¿ø ȯÀÚ½Ç
  • photoelectric cell
    ±¤ÀüÁö;±¤Àü°ü 9
  • photoelectrochemical cell
    °í¾ÆÀü±â È­ÇÐ ÀüÁö
  • porous cell(cup)
    Ãʹú±¸ÀÌ Àڱ⠿ë±â
  • primary cell
    1Â÷ ÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á